多腺苷二磷酸核糖聚合酶抑制剂联合化疗在晚期子宫内膜癌治疗中的应用价值  

Application value of poly(ADP-ribose)polymerase inhibitor combined with chemotherapy in the treatment of advanced endometrial cancer

作　　者：王梦琦[1] 杨敬敬[1] 王文桃 WANG Mengqi;YANG Jingjing;WANG Wentao(Department of Obstetrics,the Third Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China)

机构地区：[1]郑州大学第三附属医院产科,郑州4500000

出　　处：《癌症进展》2021年第13期1371-1373,1385,共4页Oncology Progress

摘　　要：目的探讨多腺苷二磷酸核糖聚合酶(PARP)抑制剂联合化疗在晚期子宫内膜癌治疗中的应用价值。方法根据治疗方法的不同将106例晚期子宫内膜癌患者分为单纯化疗组及PARP抑制剂组,每组53例。单纯化疗组患者给予环磷酰胺^(+)多柔比星^(+)卡铂化疗,PARP抑制剂组患者在此基础上口服奥拉帕利。比较两组患者卡氏功能状态(KPS)评分、血清肿瘤标志物[糖类抗原125(CA125)、糖类抗原19-9(CA19-9)]、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平]及T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))水平。结果治疗后,PARP抑制剂组患者KPS评分明显高于单纯化疗组(P﹤0.01)。治疗后,两组患者血清CA125、CA19-9、TNF-α、IL-6水平均低于本组治疗前,且PARP抑制剂组患者上述指标水平均低于单纯化疗组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平均高于本组治疗前,CD8^(+)水平均低于本组治疗前,且PARP抑制剂组患者血清CD3^(+)、CD4^(+)水平均高于单纯化疗组,CD8^(+)水平低于单纯化疗组,差异均有统计学意义(P﹤0.05)。治疗2个月后,PARP抑制剂组患者复发率及远处转移率均低于单纯化疗组,差异均有统计学意义(P﹤0.05)。结论PARP抑制剂联合化疗可改善晚期子宫内膜癌患者的免疫功能状态,抑制肿瘤进展,改善预后。Objective To investigate the application value of poly(ADP-ribose)polymerase(PARP)inhibitor combined with chemotherapy in the treatment of advanced endometrial cancer.Method According to the different treatment methods,106 patients with advanced endometrial cancer were divided into the chemotherapy alone group and PARP inhibitor group,53 patients in each group.Patients in the chemotherapy alone group were given cyclophosphamide^(+)doxorubicin^(+)carboplatin chemotherapy,and patients in the PARP inhibitor group were given olaparib orally on this basis.The Karnofsky performance status(KPS)scores,serum tumor markers[carbohydrate antigen 125(CA125)and carbohydrate antigen 19-9(CA19-9)],inflammatory factors[tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)]and T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+))levels were compared between the two groups of patients.Result After the treatment,patients in the PARP inhibitor group achieved higher KPS scores than those in the chemotherapy alone group(P<0.01).After the treatment,the serum levels of CA125,CA19-9,TNF-α,and IL-6 in the two groups were lower than those before the treatment,and the foregoing indicators in the PARP inhibitor group were lower than those in the chemotherapy alone group,the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+)and CD4^(+)in the two groups of patients were higher than those before the treatment,and the CD8^(+)levels were lower than those before the treatment,the levels of CD3^(+)and CD4^(+)in the PARP inhibitor group were higher than those in the chemotherapy alone group,and the CD8^(+)level was lower than that in the chemotherapy alone group,the differences were statistically significant(P<0.05).After 2 months of treatment,the recurrence rate and distant metastasis rate of patients in the PARP inhibitor group were lower than those in the chemotherapy alone group,the differences were statistically significant(P<0.05).Conclusion PARP inhibitor combined with chemotherapy could improve the immune

关 键 词：PARP抑制剂 T淋巴细胞亚群 子宫内膜癌 化疗 

分 类 号：R737.33[医药卫生—肿瘤]